Abstract 4400
Background
A strong scientific and public interest exists in the sustainability of pharmaceutical research and development and particularly the issue of anticancer drug prices. Despite of the number of publications, articles seem often opinion-based. To facilitate an evidence-based discourse, we reviewed the literature and produced an inventory of policy proposals. We then analyze the available quantitative evidence.
Methods
Due to the broad nature of the research question, a scoping review was performed. We combined multiple search strategies to get a systematic overview of the current body of literature.
Results
In total, we screened 4775 articles and categorized 23 proposals. 22 of 85 included articles used quantitative models. Overall, the quantitative evidence was inconclusive to deduct real world effects and evidence- based recommendations. We however identified promising solutions for further investigation: Royalty payments, prizes and rewards, two-part-pricing, price transparency, increased translational public research, and public clinical trials. At ESMO, we will present this list of promising solutions, their degree of disruptiveness and their empirical evidence. Furthermore, we will share feedback on selected solutions from a survey among European experts in the field of oncology and health regulation. Finally, we will discuss techniques of evidence based solutions facing high complexity and the need of additional data for choosing policy options.
Conclusions
Despite of the urgency of the matte of drug prices, we must realize that system consequences need careful considerations as implications for access and finances can be substantial. We advise testing promising solutions with experiments, dynamic simulations, and policy pilots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract